Healthcare
Healthcare Investment Banking Group
Finding financial solutions across every sector of the healthcare ecosystem.
A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.
Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.
Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.
Areas of Expertise
Biopharma
The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.
Healthcare Services
The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.
Healthtech
Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.
Medtech
The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.
Tools & Diagnostics
The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.
The underlying fundamentals of the biopharma sector could not be more positive, in our view. Read our 2023 half year outlook for more on what’s driving the sector.
Learn MoreNotable Transactions
$ 115,000,000
Joint Bookrunner
Biopharma | September 2023
$ 250,070,000
Joint Bookrunner
Biopharma | September 2023
$ 130,000,000
Joint Bookrunner
Biopharma | July 2023
$ 345,057,500
Joint Bookrunner
Biopharma | July 2023
£ 10,000,000
Joint Bookrunner
Healthcare | July 2023
$ 120,000,000
Joint Bookrunner
Biopharma | June 2023
$ 137,200,000
Joint Bookrunner
Biopharma | June 2023
$ 200,000,000
Investment Banker for Tricida
Biopharma | June 2023
£ 176,000,000
Financial Advisor
Medtech | April 2023
$ 460,000,000
Joint Bookrunner
Biopharma | March 2023
$ 220,800,000
Joint Bookrunner
Biopharma | February 2023
$ 20,300,000
Sole Placement Agent and Nomad
Healthcare | February 2023
$ 100,000,000
Joint Bookrunner
Medtech | February 2023
$ 227,843,965
Joint Bookrunner
Biopharma | January 2023
Advisor to Seller
Healthcare | December 2022
$ 120,000,000
Left Bookrunner
Medtech | December 2022
$ 115,799,748
Joint Bookrunner & Joint Placement Agent
Biopharma | December 2022
$ 65,010,000
Joint Bookrunner
Biopharma | December 2022
Advisor to Seller
Maritime Services, Healthcare Services | December 2022
$ 300,375,000
Joint Bookrunner
Biopharma | December 2022
$ 64,000,000
Advisor to Seller
Tools & Diagnostics | November 2022
$ 850,000,000
Financial and Capital Markets Advisor
Biopharma | November 2022
$ 115,000,000
Joint Bookrunner
Medtech | October 2022
£ 64,000,000
Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad
Healthcare Services | October 2022
$ 58,079,577
Joint Bookrunner
Biopharma | September 2022
$ 124,800,000
Joint Bookrunner
Biopharma | September 2022
$ 260,000,000
Advisor to Seller
Healthcare Services | August 2022
$ 84,249,986
Joint Bookrunner
Biopharma | August 2022
$ 143,893,750
Joint Bookrunner
Medtech | August 2022
$ 862,500,000
Lead Manager
Biopharma | August 2022
$ 104,500,000
Sole Placement Agent
Medtech | July 2022
$ 55,300,000
Sole Bookrunner
Medtech | July 2022
$ 1,200,000,000
Advisor to Seller
Medtech | July 2022
$ 250,000,000
Joint Bookrunner
Healthtech | June 2022
£ 34,261,864
Joint Bookrunner
Biopharma | May 2022
C$ 34,511,565
Joint Bookrunner
Healthtech | May 2022
$ 108,000,000
Joint Bookrunner
Biopharma | May 2022
Advisor to Seller
Healthcare Services | May 2022
$ 200,000,000
Joint Bookrunner
Biopharma | April 2022
$ 230,000,000
Joint Bookrunner
Biopharma | April 2022
€ 15,000,000
Joint Global Coordinator and Joint Bookrunner
Healthcare | April 2022
$ 30,000,000
Sole Financial Advisor and Sole Placement Agent
Medtech | March 2022
$ 230,000,000
Joint Bookrunner
Biopharma | March 2022
$ 75,000,000
Left Bookrunner
Biopharma | March 2022
$ 40,000,000
Financial Advisor
Healthtech | March 2022
$ 2,350,000,000
Joint Bookrunner
Healthtech | February 2022
$ 100,000,000
Joint Bookrunner
Biopharma | January 2022
$ 98,000,000
Joint Bookrunner
Biopharma | January 2022
Advisor to Seller
Healthcare Services | December 2021
$ 52,325,000
Joint Bookrunner
Biopharma | December 2021
C$ 65,000,000
Co-Lead Manager
Healthtech | November 2021
$ 172,500,000
Left Bookrunner
Biopharma | November 2021
$ 80,500,000
Joint Bookrunner
Medtech | November 2021
$ 43,000,000
Lead Placement Agent
Biopharma | November 2021
$ 100,800,000
Joint Bookrunner
Tools & Diagnostics | November 2021
$ 158,000,000
Capital Markets Advisor
Healthtech | November 2021
Advisor to Seller
Healthcare Services | November 2021
$ 230,000,000
Joint Bookrunner
Healthcare Services | November 2021
$ 93,600,000
Joint Bookrunner
Medtech | October 2021
$ 150,750,000
Joint Bookrunner
Biopharma | October 2021
C$ 7,004,400
Joint Bookrunner
Life Sciences & Healthcare | October 2021
$ 74,865,000
Joint Bookrunner
Medtech | October 2021
$ 345,000,000
Joint Bookrunner
Medtech | October 2021
$ 70,900,000
Advisor to Buyer
Medtech | October 2021
Advisor to Seller
Medtech | October 2021
$ 13,200,000
Joint Bookrunner
Healthcare Services | September 2021
Advisor to Buyer
Medtech | September 2021
$ 1,000,000,000
Joint Bookrunner
Biopharma | September 2021
$ 651,000,000
Capital Markets Advisor
Tools & Diagnostics | September 2021
Advisor to Buyer
Biopharma | August 2021
$ 212,000,000
Capital Markets Advisor
Biopharma | August 2021
$ 355,810,000
Joint Bookrunner
Biopharma | August 2021
$ 84,333,337
Joint Bookrunner
Biopharma | July 2021
$ 230,000,000
Joint Bookrunner
Tools & Diagnostics | July 2021
Advisor to Seller
Biopharma | July 2021
£ 17,000,000
Sole Global Coordinator, Joint Bookrunner & Nomad
Healthtech | July 2021
$ 174,560,000
Joint Bookrunner
Biopharma | July 2021
$ 180,132,080
Joint Bookrunner
Tools & Diagnostics | July 2021
$ 62,675,000
Joint Bookrunner
Medtech | July 2021
$ 100,190,000
Joint Bookrunner
Biopharma | July 2021
$ 350,000,000
Joint Bookrunner
Biopharma | July 2021
$ 97,807,500
Joint Bookrunner
Medtech | July 2021
$ 181,500,000
Advisor to Seller
Biopharma | July 2021
$ 160,000,000
Joint Bookrunner
Biopharma | June 2021
$ 160,000,000
Joint Bookrunner
Biopharma | June 2021
$ 80,000,000
Left Bookrunner
Entertainment | June 2021
Advisor to Seller
Healthcare Services | June 2021
$ 366,000,000
Co-Manager
Medtech | April 2021
$ 98,325,000
Joint Bookrunner
Biopharma | April 2021
$ 100,912,500
Joint Bookrunner
Medtech | April 2021
$ 287,500,000
Joint Bookrunner
Biopharma | April 2021
$ 646,875,000
Joint Bookrunner
Tools & Diagnostics | April 2021
$ 550,000,000
Joint Bookrunner
Biopharma | April 2021
$ 103,500,000
Joint Bookrunner
Biopharma | March 2021
$ 50,652,000
Left Bookrunner
Biopharma | March 2021
$ 30,000,000
Joint Bookrunner
Biopharma | March 2021
$ 48,000,000
Joint Bookrunner
Biopharma | March 2021
$ 55,000,000
Joint Placement Agent
Biopharma | March 2021
$ 56,000,000
Joint Bookrunner
Biopharma | March 2021
$ 218,500,000
Joint Bookrunner
Biopharma | March 2021
$ 115,000,000
Joint Bookrunner
Healthtech | March 2021
$ 160,425,000
Joint Bookrunner
Biopharma | March 2021
$ 138,250,000
Sole Bookrunner
Medtech | March 2021
$ 90,000,000
Advisor to Squadron
Medtech | March 2021
$ 222,250,000
Joint Bookrunner
Healthtech | February 2021
$ 60,000,000
Joint Bookrunner
Healthtech | February 2021
$ 2,200,000,000
Co-Manager
Healthcare Services | February 2021
$ 150,000,000
Joint Bookrunner
Healthtech | February 2021
$ 42,000,000
Sole Bookrunner
Medtech | February 2021
$ 117,000,000
Joint Bookrunner
Biopharma | February 2021
$ 264,500,000
Joint Bookrunner
Biopharma | February 2021
$ 203,439,942
Joint Bookrunner
Biopharma | February 2021
Capital Markets Advisor
Biopharma | February 2021
£ 40,000,000
Sole Placement Agent
Biopharma | February 2021
$ 74,500,000
Left Bookrunner
Biopharma | February 2021
$ 70,000,000
Joint Placement Agent
Healthtech | February 2021
$ 129,375,000
Joint Bookrunner
Biopharma | January 2021
$ 168,000,000
Joint Bookrunner
Biopharma | January 2021
$ 103,500,000
Joint Bookrunner
Biopharma | January 2021
$ 264,000,000
Joint Bookrunner
Healthcare Services | January 2021
$ 555,450,000
Joint Bookrunner
Biopharma | December 2020
$ 149,500,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 200,000,000
Joint Bookrunner
Biopharma | December 2020
$ 345,080,500
Joint Bookrunner
Biopharma | December 2020
$ 312,225,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 750,000,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 277,725,000
Joint Bookrunner
Biopharma | December 2020
$ 1,863,000,000
Joint Bookrunner
Tools & Diagnostics | November 2020
$ 81,176,464
Joint Bookrunner
Biopharma | November 2020
$ 345,000,000
Lead Manager
Medtech | October 2020
$ 104,796,260
Left Bookrunner
Medtech | October 2020
$ 1,898,938,296
Joint Financial Advisor
Biopharma | October 2020
$ 2,128,500,000
Lead Manager
Medtech | October 2020
$ 200,000,000
Joint Bookrunner
Biopharma | September 2020
$ 277,761,104
Joint Bookrunner
Biopharma | September 2020
$ 267,696,966
Joint Bookrunner
Biopharma | September 2020
$ 963,470,000
Joint Bookrunner
Biopharma | August 2020
$ 140,000,000
Advisor to Seller
Biopharma | August 2020
$ 140,000,000
Advisor to Seller
Biopharma | August 2020
$ 135,000,000
Advisor to Buyer
Biopharma | July 2020
$ 445,000,000
Financial Advisor
Biopharma | July 2020
$ 209,000,000
Joint Bookrunner
Biopharma | July 2020
$ 80,000,000
Lead Placement Agent
Biopharma | July 2020
$ 120,000,000
Joint Bookrunner
Biopharma | July 2020
$ 39,054,798
Advisor to Buyer
Medtech | April 2020
$ 79,347,051
Joint Bookrunner
Biopharma | March 2020
$ 125,000,000
Financial Advisor
Biopharma | February 2019
Advisor to Seller
Biopharma | September 2018